Leadership Overview
Ultragenyx has 4 executives leading key functions including financial strategy, portfolio management, human resources, and clinical development.
Focused on rare genetic disease therapeutics, Ultragenyx advances innovative biologics and small-molecule treatments to address significant unmet medical needs across global markets.
Focused on rare genetic disease therapeutics, Ultragenyx advances innovative biologics and small-molecule treatments to address significant unmet medical needs across global markets.
Leadership Roles at Ultragenyx
Howard Horn - Chief Financial Officer & Executive VP, Corporate Strategy
Howard Horn, the Chief Financial Officer & Executive VP, Corporate Strategy at Ultragenyx, directs all fiscal operations and long-term capital allocation. Managing the financial health of the organization, the Chief Financial Officer & Executive VP, Corporate Strategy oversees investor relations and corporate planning to support the development of rare disease therapeutics. This leadership role involves balancing complex R&D investments with sustainable growth objectives across North American and European markets. By optimizing the capital structure, Howard Horn directly impacts the ability of the company to fund clinical programs for metabolic and bone disorders. Furthermore, the Chief Financial Officer & Executive VP, Corporate Strategy collaborates with the Board to refine strategic priorities, ensuring that financial resources align with the mission of delivering life-changing treatments to patients with limited options.

Alyssa Moore - Chief of Staff and Head Senior Vice President, Program and Portfolio Management
Alyssa Moore, the Chief of Staff and Head Senior Vice President, Program and Portfolio Management at Ultragenyx, coordinates cross-functional execution across the entire drug development pipeline. Overseeing the integration of clinical programs, the Chief of Staff and Head Senior Vice President, Program and Portfolio Management ensures that research milestones meet rigorous internal standards. This role involves managing the lifecycle of biologics and small-molecule therapeutics, facilitating communication between scientific teams and executive leadership. By streamlining operational workflows, Alyssa Moore drives efficiency in the advancement of treatments for rare genetic conditions. The Chief of Staff and Head Senior Vice President, Program and Portfolio Management also monitors global portfolio health, identifying potential bottlenecks in clinical trials to maintain momentum in the competitive biopharmaceutical landscape while supporting the overarching corporate strategy.
Ernie Meyer - Executive Vice President & Chief Human Resources Officer
Ernie Meyer, the Executive Vice President & Chief Human Resources Officer at Ultragenyx, directs talent acquisition and organizational development initiatives. Cultivating a high-performance culture, the Executive Vice President & Chief Human Resources Officer manages global workforce planning to support the expansion of clinical research capabilities. This leadership role involves designing compensation structures and professional development programs that attract top-tier scientific talent to the biopharmaceutical sector. By fostering an environment of innovation, Ernie Meyer ensures that the company retains the expertise necessary to tackle complex genetic disorders. The Executive Vice President & Chief Human Resources Officer also aligns human capital strategies with the broader mission of addressing unmet medical needs, ensuring that internal teams remain agile and focused on the successful delivery of therapeutic solutions across international operations.
Eric Crombez - Chief Medical Officer & Executive Vice President
Eric Crombez, the Chief Medical Officer & Executive Vice President at Ultragenyx, directs all clinical development and medical affairs activities. Overseeing the design and execution of global clinical trials, the Chief Medical Officer & Executive Vice President ensures that therapeutic candidates for rare genetic diseases meet safety and efficacy benchmarks. This role involves collaborating with regulatory agencies and research institutions to advance the pipeline of metabolic and enzyme deficiency treatments. By providing medical oversight, Eric Crombez directly impacts the success of clinical programs in North America, Europe, and Asia. The Chief Medical Officer & Executive Vice President also guides the scientific strategy, ensuring that patient-centric data informs every stage of drug development, ultimately accelerating the path toward providing effective therapies for patients suffering from ultra-rare genetic conditions.
Explore Leadership Teams in Chemicals & Related Products
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.
Company Leadership SL
SM
AL
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers.
Company Leadership
JS
RA

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.
Company Leadership KR
CB


Established in 1978 and headquartered in London, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.
Company Leadership
TD
